Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer
Status:
Completed
Trial end date:
2008-09-22
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing of die.
PURPOSE: Randomized phase II trial to compare the effectiveness of two treatment regimens of
lurtotecan liposome in patients who have advanced or recurrent ovarian epithelial cancer,
primary fallopian tube cancer, or peritoneal cancer that has been previously treated with
chemotherapy.